Published in N Engl J Med on February 03, 1994
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer (2013) 1.93
Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg (2012) 1.43
Evaluation of New-Onset Ascites. JAMA (2016) 1.39
Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH). Br J Cancer (2004) 0.99
Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol (2011) 0.99
Cryptococcal Peritonitis Complicating Hepatic Failure: Case Report and Review of the Literature. J Appl Res (2006) 0.98
Chylous Ascites: Evaluation and Management. ISRN Hepatol (2014) 0.97
Myxedema ascites: case report and literature review. J Korean Med Sci (2006) 0.96
Myxedema ascites with high CA-125: Case and a review of literature. World J Hepatol (2013) 0.95
Cirrhosis and its complications: evidence based treatment. World J Gastroenterol (2014) 0.93
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol (2013) 0.91
Continuous peritoneal drainage of large-volume ascites. Dig Dis Sci (2011) 0.90
Evaluation and management of patients with refractory ascites. World J Gastroenterol (2009) 0.89
Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology. J Clin Pathol (2001) 0.88
Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. Dig Dis Sci (1997) 0.87
Management of ascites due to gastrointestinal malignancy. Ann Saudi Med (2009) 0.85
Transient elastography with the XL probe rapidly identifies patients with nonhepatic ascites. Hepat Med (2012) 0.84
Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution. Dig Dis Sci (1997) 0.83
Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res (2010) 0.82
Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health (2012) 0.81
The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. Int J Clin Exp Med (2014) 0.79
Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro. BMC Cancer (2015) 0.79
Low gradient ascites: a seven-year course review. World J Gastroenterol (2005) 0.78
Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites. Clin Epigenetics (2016) 0.77
Ascites. Curr Treat Options Gastroenterol (2001) 0.76
Ascites in Ovarian Carcinoma - Reliability and Limitations of Cytological Analysis. West Indian Med J (2015) 0.76
Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. Saudi J Gastroenterol (2014) 0.76
Large-volume paracentesis with indwelling peritoneal catheter and albumin infusion: a community hospital study. J Community Hosp Intern Med Perspect (2016) 0.75
Development and validation of the self-completed ascites impact measure to understand patient motivation for requesting a paracentesis. Patient Relat Outcome Meas (2012) 0.75
New Biochemical Parameters in the Differential Diagnosis of Ascitic Fluids. Gastroenterology Res (2016) 0.75
Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies. World J Gastroenterol (2004) 0.75
Chronic constrictive pericarditis. Case Rep Cardiol (2013) 0.75
Care of patients with ascites. N Engl J Med (1994) 0.75
Management options in decompensated cirrhosis. Hepat Med (2015) 0.75
Which one of the following statements about the use of paracentesis in the management of ascites is true? Can Fam Physician (1995) 0.75
Malignant Pleural Effusion and Ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-Like Cell Properties via VEGF/PI3K/Akt/mTOR Pathway. J Biol Chem (2016) 0.75
Low dose albumin for the prevention of renal impairment following large volume paracentesis in cirrhosis. Pak J Med Sci (2015) 0.75
Care of patients with ascites. N Engl J Med (1994) 0.75
Care of patients with ascites. N Engl J Med (1994) 0.75
Chylous Ascites: A Rare Adverse Effect of Methimazole Treatment for Grave's Disease-A Case Report and Review of the Literature. Case Rep Endocrinol (2015) 0.75
Concave Margin Sign on CT as an Indication of Ascites. Radiol Case Rep (2015) 0.75
NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis. ISRN Hepatol (2013) 0.75
Risk factors and long-term outcome for postoperative intra-abdominal infection after hepatectomy for hepatocellular carcinoma. Medicine (Baltimore) (2017) 0.75
Azelnidipine-induced chyloperitoneum in a patient with microscopic polyangiitis. Clin Exp Nephrol (2010) 0.75
Clinical Features of Refractory Ascites in Outpatients. Clinics (Sao Paulo) (2017) 0.75